Is Belite Bio, Inc (BLTE) a Buy, Sell, or Hold?
Belite Bio, Inc
NASDAQ:BLTE
$146.68 USD
-$0.35 (-0.24%)
- Volume
- 107.87K
- Average Volume
- 190.82K
- Market Capitalization
- $5.88B
- P/E Ratio
- -57.52
- Dividend Yield
- 0.00%
- Price Target
- $216.00
- Year High
- $200.00
- Year Low
- $59.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $33.71
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Yu-Hsin Lin |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BLTE |
| CUSIP | 07782B104 |
| CIK | 0001889109 |
| Web | https://belitebio.com |
| Phone | 858-246-6240 |
| Currency | USD |
| Employees | 41 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 33.71 |
| Quick Ratio | 33.71 |
| Cash Ratio | 0.00 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | 0.00 |
| Price / Cash Flow | -556629.84 |
| Price / Book | 7.35 |
Price Target and Rating
| Average Stock Price Forecast | $216.00 |
| High Stock Price Forecast | $217.00 |
| Low Stock Price Forecast | $200.00 |
| Forecast Upside/Downside | -32.09% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.31 |
| Trailing P/E Ratio | -57.52 |
| PEG Ratio | 1.07 |
| P/E Growth | 1.07 |
| Net Income | $-77.61M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -18.14% |
| Return on Assets | -11.13% |
Financials Score
| AltmanZ Score | 228.75 |
| Piotroski Score | 2.00 |
| Working Capital | 506.38M |
| Total Assets | 811.27M |
| Ebit | -95.63M |
| Market Cap | 5.89B |
| Total Liabilities | 15.48M |
Poll Results
About Belite Bio, Inc (NASDAQ:BLTE) Stock
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis ... , and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
2026-07-09 23:03:22
Belite Bio NASDAQ: BLTE Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment for Stargardt disease and geographic atrophy secondary to age-related macular degeneration, two severe retinal diseases with overlapping features.
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
2026-07-06 08:00:00
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday, July 9, 2026, at 12:30 pm ET.
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
2026-07-06 07:00:00
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Belite data will be presented at the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV) being held on July 6-11, 2026, in Sydney, Australia, and the American Society of Retina Specialists (ASRS) 2026 Annual Meeting being held on July 15-18, 2026, in Montréal, Canada.
2026-06-12 21:30:00
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.
2026-06-12 21:30:00
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.
2026-06-08 19:28:30
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-02 08:00:00
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 pm ET. Webcast Link Instructions Webcasts of the presentations can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events.
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
2026-05-20 19:20:58
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Belite Bio, Inc (BLTE) stock price?
-
Belite Bio, Inc(NASDAQ:BLTE) stock price is $146.68 in the last trading session. During the trading session, BLTE stock reached the peak price of $200 while $59.12 was the lowest point it dropped to. The percentage change in BLTE stock occurred in the recent session was --0.24% while the dollar amount for the price change in BLTE stock was -$-0.35.
-
BLTE's industry and sector of operation?
-
The NASDAQ listed BLTE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BLTE?
-
Hendrik Scholl | Chief Medical Officer
Nathan L. Mata | Chief Scientific Officer
Yu-Hsin Lin | Chairman of the Board of Directors & Chief Executive Officer
Hao-Yuan Chuang | Chief Financial Officer & Director
| -
How many employees does BLTE have?
-
Number of BLTE employees currently stands at 41. BLTE operates from 5820 Oberlin Drive, San Diego, CA 92121, US.
-
Link for BLTE official website?
-
Official Website of BLTE is: https://belitebio.com
-
How do I contact BLTE?
-
BLTE could be contacted at phone #858-246-6240 and can also be accessed through its website. BLTE operates from 5820 Oberlin Drive, San Diego, CA 92121, US.
-
How many shares of BLTE are traded daily?
-
The average number of BLTE shares traded daily for last 3 months was 190.82K.
-
What is the market cap of BLTE currently?
-
The market value of BLTE currently stands at $5.88B with its latest stock price at $146.68